Clinical Trial Update: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites [Phase 2]

View source ↗

Summary

Phase II study evaluating dabrafenib and trametinib as pre- and post-operative therapy in melanoma patients with brain metastases; the trial is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma and Brain Metastases | Phase 2 | Status: TERMINATED | Results posted: 2018-08-17